Results 141 to 150 of about 25,067 (205)

From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer. [PDF]

Drugs Real World Outcomes
Bosch D, van der Velden KJM, Beeker A, van den Berg HP, Bergman AM, van der Doelen MJ, van den Eertwegh AJM, Hendriks MP, Kerkhofs TMA, van de Luijtgaarden ACM, Mehra N, van Moorselaar RJA, Tascilar M, Vervenne WL, Weijl NI, Uyl-de Groot CA, Mulders PFA, Kuppen MCP, van Oort IM.   +18 more
europepmc   +1 more source

Real-world uptake of gBRCA testing as a companion diagnostic for olaparib in patients with high-risk HER2-negative early breast cancer in Japan: a cross-sectional multicenter study (BRCAwareness). [PDF]

Breast Cancer
Taji T, Uemura Y, Kimura Y, Maeda N, Ito A, Seki H, Takabatake D, Harao M, Nakamoto S, Matsunuma R, Koganezawa C, Iwamoto T, Mukai H, Kikawa Y.   +13 more
europepmc   +1 more source

DNER drives glycolytic reprogramming in renal cell carcinoma by activating the JAK2/STAT3 signaling pathway. [PDF]

Front Immunol
Li A, Xu JW, Qin JH, Yuan Q, Teng L.
europepmc   +1 more source

A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number-High/p53-Abnormal Endometrial Cancer. [PDF]

Clin Cancer Res
Rubinstein MM, Ge JY, Zhou Q, Iasonos A, Weigelt B, Selenica P, Muldoon DM, Bandlamudi C, Kaczynski C, Paroder V, Higgins K, Shah P, Weissblum S, Lyn A, Liu YL, Bose S, Cohen SM, Green AK, Grisham RN, Kyi C, O'Cearbhaill RE, Tew WP, Berger MF, Aghajanian C, Makker V.   +24 more
europepmc   +1 more source

Autophagy impairs the sensitivity of Ewing sarcoma cells to PARP inhibitors. [PDF]

Cancer Chemother Pharmacol
Clausen J, Kocher D, Schadwinkel HM, Becker S, Milde T, Beck JF, Sonnemann J.   +6 more
europepmc   +1 more source

Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition). [PDF]

Cancer Innov
Ma F, Xu B, China Anti‐Cancer Association Committee on Clinical Research of Anticancer Drugs, National Expert Committee on Monitoring Clinical Application of Antineoplastic Drugs, Breast Cancer Expert Committee of National Cancer Quality Control Center, Expert Committee on Chemotherapy Quality Control of Beijing Cancer Treatment Quality Control and Improvement Center.   +5 more
europepmc   +1 more source

Cannabidiol potentiates olaparib-induced cytotoxicity through cell cycle arrest and DNA damage modulation in breast cancer cells. [PDF]

Mol Cell Biochem
Deniz C, Yüksel B, Cebeci E, Şahin F.
europepmc   +1 more source

Inactivation of PRMT5 by PARP Inhibitors Confers High Susceptibility in MTAP-Deficient Cancers. [PDF]

Cancers (Basel)
Liu Q, Sheng Y, Lin F, Tan H, Chang Y, Lu X, Chen H, Du C.   +7 more
europepmc   +1 more source

First Real-World Data of Olaparib Combination Treatment with Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC): Descriptive Analysis of 154 Patients Enrolled in the Early Access Program in France. [PDF]

Drugs Real World Outcomes
Dourthe LM, Guillot A, Vassal C, Kazan E, Coeffic D, Rebischung C, Suau D, Lahouegue A, Aboulabbes S, Falabrègues A, Ould Lahsen H.   +10 more
europepmc   +1 more source